Skip to main content
. 2017 Apr 20;13(6):4917–4924. doi: 10.3892/ol.2017.6061

Table III.

Treatment characteristics in pancreatic adeno-carcinoma patients (n=42).

Treatment Patients, n (%)
Folfirinox followed by GEM, total number of chemotherapy regimens received
  2 42 (100.0)
  3 17 (40.5)
  4 3 (7.0)
Folfirinox response at 2 months
  Disease controlled (disease stabilization or partial response) 28 (66.6)
  Disease progression 12 (28.6)
  NA 2 (4.8)
Treatment interruption following first-line therapy
  Patients, n (%) 12 (28.6)
  Time to second-line therapy, months 3.4
GEM response at 2 months
  Disease controlled (disease stabilization or partial response) 11 (26.0)
  Disease progression 31 (74.0)
GEM toxicity, maximum grade observed
  1 5 (11.9)
  2 6 (14.3)
  3 6 (14.3)
  Treatment interruption 1 (2.4)

GEM, gemcitabine; NA, not available.